Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anja Möricke

Showing results (1-10 of 88) with videos related to

Pageof 9
Sort By:
Pediatric Blood & Cancer|February 22, 2011
Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trialDominik Schrey, Katharina Speitel, Claudia Lanvers-Kaminsky, et al.
International Journal of Hematology|April 9, 2009
Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: a case-control studyEkaterini Kidas, Anja Möricke, Rita Beier, et al.
Leukemia Research|May 15, 2012
PAX5-AUTS2: a recurrent fusion gene in childhood B-cell precursor acute lymphoblastic leukemiaDagmar Denk, Karin Nebral, Jutta Bradtke, et al.
Annals of Hematology|June 4, 2008
Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemiaGunnar Cario, Andrea Fetz, Christian Bretscher, et al.
Blood Cells, Molecules & Diseases|May 29, 2007
Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study GroupMartin Stanulla, Gunnar Cario, Barbara Meissner, et al.
Pediatric Blood & Cancer|January 29, 2010
Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007Dominik Schrey, Stephan Borghorst, Claudia Lanvers-Kaminsky, et al.
Blood|May 9, 2013
Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemiaSusanne Radtke, Oliver Zolk, Bertold Renner, et al.
European Journal of Drug Metabolism and Pharmacokinetics|March 29, 2017
Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar<sup>®</sup> in Children with Acute Lymphoblastic LeukemiaGudrun Würthwein, Claudia Lanvers-Kaminsky, Georg Hempel, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2007
Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhoodAnja Borgmann, Christina Zinn, Reinhard Hartmann, et al.
European Journal of Pediatric Surgery : Official Journal of Austrian Association of Pediatric Surgery ... [Et Al] = Zeitschrift Fur Kinderchirurgie|September 26, 2017
Surgical Implications for Diagnosis and Treatment of Intestinal Aspergillosis in Pediatric Patients with ALLJanina Fischer, Thorsten Simon, Axel Hamprecht, et al.
Pageof 9

Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
Pediatric Blood & Cancer|February 22, 2011
Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trialDominik Schrey, Katharina Speitel, Claudia Lanvers-Kaminsky, et al.
International Journal of Hematology|April 9, 2009
Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: a case-control studyEkaterini Kidas, Anja Möricke, Rita Beier, et al.
Leukemia Research|May 15, 2012
PAX5-AUTS2: a recurrent fusion gene in childhood B-cell precursor acute lymphoblastic leukemiaDagmar Denk, Karin Nebral, Jutta Bradtke, et al.
Annals of Hematology|June 4, 2008
Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemiaGunnar Cario, Andrea Fetz, Christian Bretscher, et al.
Blood Cells, Molecules & Diseases|May 29, 2007
Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study GroupMartin Stanulla, Gunnar Cario, Barbara Meissner, et al.
Pediatric Blood & Cancer|January 29, 2010
Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007Dominik Schrey, Stephan Borghorst, Claudia Lanvers-Kaminsky, et al.
Blood|May 9, 2013
Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemiaSusanne Radtke, Oliver Zolk, Bertold Renner, et al.
European Journal of Drug Metabolism and Pharmacokinetics|March 29, 2017
Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar<sup>®</sup> in Children with Acute Lymphoblastic LeukemiaGudrun Würthwein, Claudia Lanvers-Kaminsky, Georg Hempel, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2007
Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhoodAnja Borgmann, Christina Zinn, Reinhard Hartmann, et al.
European Journal of Pediatric Surgery : Official Journal of Austrian Association of Pediatric Surgery ... [Et Al] = Zeitschrift Fur Kinderchirurgie|September 26, 2017
Surgical Implications for Diagnosis and Treatment of Intestinal Aspergillosis in Pediatric Patients with ALLJanina Fischer, Thorsten Simon, Axel Hamprecht, et al.
Pageof 9